All News

A retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS)

Agency officials have given the green light to versions of buprenorphine and naloxone (Suboxone, Mylan Technologies Inc and Dr. Reddy's Laboratories SA) sublingual film.

Here is why to consider the dollars and data behind such pharmacy offerings.

Top news of the week from Specialty Pharmacy Times.

Those who can do this find that they have an advantage in dealing with patients, team members, and vendors.

Some vitamin deficiencies go unnoticed, but insidious vitamin deficiencies can make us miserable.

Timolol eyedrops may have a potential role in managing acute migraine for some patients.

Top news of the day from across the health care landscape

In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment.

A 2-part trial shows a new antibody that suppresses HIV when combined with antiretroviral therapy (ART).

Despite universal access to care afforded to US military service members, there is a need to improve and expand access to PrEP for those patients at highest risk for HIV infection.

The 2017-2018 flu season was severe, resulting in 172 pediatric deaths across the country.

Top news of the day from across the health care landscape

As the age of technology continues to blossom, people are spending upwards of 10 hours per day looking at screens—4 hours longer than recommended by physicians.

Officials with the FDA have granted accelerated approval to pembrolizumab (Keytruda, Merck) for 2 new indications, including the treatment of refractory primary mediastinal large B-cell lymphoma (PMBCL), and recurrent metastatic cervical cancer in previously treated patients whose tumors express PD-L1.

Officials with the FDA have approved bevacizumab (Avastin, Genentech) in combination with carboplatin and paclitaxel for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pembrolizumab (Keytruda, Merck) gained FDA approval for 2 new oncology indications.

Officials with the FDA have approved bevacizumab (Avastin, Genentech) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel.

The results of a new analysis have revealed that incidence of intensive care unit bacteremia is decreasing over time.

On National HIV Testing Day, which takes place on June 27, Walgreens and Greater Than AIDS will team up with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

As a result of the persistent opioid epidemic, a current harm reduction initiative focuses on reducing adverse consequences in drug users.

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA.

At the American Pharmacy Purchasing Alliance's PharmCon, Michael Castagna, PharmD, MBA, and CEO of Mannkind Corporation discussed the need for a larger focus on patient outcomes in order to better address the diabetes pandemic occurring in the United States.

Administering high doses of vitamin D over relatively short timeframes was associated with increased likelihood of toxicity, in a recent study.

In a recent study, researchers set out to identify the reasons why prescribers and pharmacists continue to prescribe NS β‐blockers despite the guidelines recommending against it.

If a governmental agency and/or a PBM nevertheless concludes that the arrangement is “gaming the system,” then the agency/PBM will likely be motivated to bring the arrangement to an end.